Developing an Antigen-Specific NanoDisc Platform for Immune Tolerance: From Platform Design to Clinical Translation in Celiac Disease

• Describe EVOQ Therapeutics’ NanoDisc platform for the antigen-specific induction of immune tolerance and the principles guiding antigen and formulation design
• EVOQ’s celiac disease program as a translational case study, highlighting the progression from preclinical development toward clinical evaluation and the opportunities celiac disease provides for assessing antigen-specific pharmacodynamic responses
• Discuss how a modular NanoDisc platform may be applied across autoimmune diseases in which disease-relevant antigens are known

Speakers:

Weston Daniel

Chief Development Officer

EVOQ Therapeutics